Lei Yu, Liu Jiacheng, Bai Yaowei, Zheng Chuansheng, Wang Dongyuan
Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.
Hubei Provincial Clinical Research Center for Precision Radiology & Interventional Medicine, Wuhan 430022, China.
Pharmaceutics. 2025 Jan 1;17(1):46. doi: 10.3390/pharmaceutics17010046.
The emergence of effective immunotherapies has revolutionized therapies for many types of cancer. However, current immunotherapy has limited efficacy in certain patient populations and displays therapeutic resistance after a period of treatment. To address these challenges, a growing number of immunotherapy drugs have been investigated in clinical and preclinical applications. The diverse functionality of peptides has made them attractive as a therapeutic modality, and the global market for peptide-based therapeutics is witnessing significant growth. Peptides can act as immunotherapeutic agents for the treatment of many malignant cancers. However, a systematic understanding of the interactions between different peptides and the host's immune system remains unclear. This review describes in detail the roles of peptides in regulating the function of the immune system for cancer immunotherapy. Initially, we systematically elaborate on the relevant mechanisms of cancer immunotherapy. Subsequently, we categorize peptide-based nanomaterials into the following three categories: peptide-based vaccines, anti-cancer peptides, and peptide-based delivery systems. We carefully analyzed the roles of these peptides in overcoming the current barriers in immunotherapy, including multiple strategies to enhance the immunogenicity of peptide vaccines, the synergistic effect of anti-cancer peptides in combination with other immune agents, and peptide assemblies functioning as immune stimulators or vehicles to deliver immune agents. Furthermore, we introduce the current status of peptide-based immunotherapy in clinical applications and discuss the weaknesses and future prospects of peptide-based materials for cancer immunotherapy. Overall, this review aims to enhance comprehension of the potential applications of peptide-based materials in cancer immunotherapy and lay the groundwork for future research and clinical applications.
有效的免疫疗法的出现彻底改变了多种癌症的治疗方式。然而,目前的免疫疗法在某些患者群体中的疗效有限,且在治疗一段时间后会出现治疗抗性。为应对这些挑战,越来越多的免疫疗法药物已在临床和临床前应用中得到研究。肽的多样功能使其成为一种有吸引力的治疗方式,基于肽的治疗药物的全球市场正在显著增长。肽可作为免疫治疗剂用于治疗多种恶性癌症。然而,对于不同肽与宿主免疫系统之间相互作用的系统理解仍不明确。本综述详细描述了肽在调节癌症免疫治疗中免疫系统功能方面的作用。首先,我们系统阐述了癌症免疫治疗的相关机制。随后,我们将基于肽的纳米材料分为以下三类:基于肽的疫苗、抗癌肽和基于肽的递送系统。我们仔细分析了这些肽在克服当前免疫治疗障碍方面的作用,包括增强肽疫苗免疫原性的多种策略、抗癌肽与其他免疫剂联合使用的协同效应,以及作为免疫刺激剂或递送免疫剂载体的肽组装体。此外,我们介绍了基于肽的免疫疗法在临床应用中的现状,并讨论了基于肽的材料在癌症免疫治疗中的弱点和未来前景。总体而言,本综述旨在增进对基于肽的材料在癌症免疫治疗中潜在应用的理解,并为未来的研究和临床应用奠定基础。